It has been reported that inflammation, indicated by C-reactive protein (hs-CRP), and hyperglycaemia, indicated by haemoglobin A1c (HbA1c), jointly contribute to the cardiovascular risk of patients with metabolic disease complications. This evidence concerns the gene CRP and Other metabolic disease.